Literature DB >> 19504394

Does a diffuse growth pattern predict for survival in patients with low-grade follicular lymphoma?

Sharathkumar Bhagavathi1, Keni Gu, Fausto R Loberiza, Martin Bast, Julie M Vose, Dennis D Weisenburger.   

Abstract

Low-grade follicular lymphoma (LGFL) is known to have a good prognosis. However, the clinical relevance of the presence and extent of diffuse growth areas within LGFL is not clear. Therefore, we studied 457 patients with nodal LGFL seen over a 20-year period (1982-2002). Relevant clinical and survival data were obtained and the pathology specimens were subclassified into predominantly follicular LGFL (>or=80% follicular areas), significantly follicular LGFL (30-70% follicular areas), significantly diffuse LGFL (<30% follicular areas) and pure diffuse follicle centre lymphoma (DFCL). The majority of the patients were treated with anthracycline-based regimens. Patients with DFCL were slightly older (median age, 67 years), more likely to have bulky disease (>5 cm), and often had suboptimal biopsies. However, no association was observed between the extent of diffuse areas and survival across the four subgroups. We conclude that the subclassification of LGFL based on the extent of diffuse areas does not have clinical relevance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19504394     DOI: 10.1080/10428190902919192

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  New developments in the pathology of malignant lymphoma: a review of the literature published from January to August 2009.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-09-26       Impact factor: 0.196

2.  CREBBP and STAT6 co-mutation and 16p13 and 1p36 loss define the t(14;18)-negative diffuse variant of follicular lymphoma.

Authors:  Rena R Xian; Yi Xie; Lisa M Haley; Raluca Yonescu; Aparna Pallavajjala; Stefania Pittaluga; Elaine S Jaffe; Amy S Duffield; Chad M McCall; Shereen M F Gheith; Christopher D Gocke
Journal:  Blood Cancer J       Date:  2020-06-17       Impact factor: 11.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.